Atypical antipsychotic profile of flunarizine in animal models

Psychopharmacology

Volumn 177, Issue 3, 2005, Pages 344-348

  Tort, Adriano B L ^a   Dall'Igna, Oscar P ^a   De Oliveira, Ricardo V ^a   Mantese, Carlos E A ^a   Fett, Paulo ^a   Gomes, Márcio W S ^a   Schuh, Juliana ^a   Souza, Diogo O ^a   Lara, Diogo R ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Amphetamine; Antipsychotic; Dizocilpine; Flunarizine; Locomotion; Schizophrenia

Indexed keywords

AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; DIZOCILPINE; FLOMOXEF; FLUNARIZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HYPERACTIVITY; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADMINISTRATION, ORAL; ANIMALS; CATALEPSY; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FLUNARIZINE; HALOPERIDOL; MICE; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 12344327435     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1955-y     Document Type: Article

References (34)

1. 1 receptors. Eur J Pharmacol 197:221-223
2. 2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab 15:513-518
3. Chouza C, Scaramelli A, Caamano JL, De Medina O, Aljanati R, Romero S (1986) Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1:1303-1304
4. Ellenbroek BA (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57:1-78
5. Farber NB, Jiang XP, Heinkel C, Nemmers B (2002) Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry 7:726-733
6. Feinberg I, Campbell IG (1998) Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: implications for the PCP model of schizophrenia. Neuroreport 9:2189-2193
7. Grebb JA (1986) Nifedipine and flunarizine block amphetamine-induced behavioral stimulation in mice. Life Sci 38:2375-2381
8. Haraguchi K, Ito K, Kotaki H, Sawada Y, Iga T (1998) Catalepsy induced by calcium channel blockers in mice. Biopharm Drug Dispos 19:115-122
9. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS (1984) Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 27:6-44
10. Hori Y, Takeda H, Tsuji M, Matsumiya T (1998) Differentiation of the inhibitory effects of calcium antagonists on abnormal behaviors induced by methamphetamine or phencyclidine. Pharmacology 56:165-174
11. Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13-23
12. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369
13. Kariya S, Isozaki S, Masubuchi Y, Suzuki T, Narimatsu S (1995) Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine. Biochem Pharmacol 50:1645-1650
14. Karow A, Naber D (2002) Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 162:3-10
15. Lara DR, Souza DO (2000) Schizophrenia: a purinergic hypothesis. Med Hypoth 54:157-166
16. Leone M, Grazzi L, La Mantia L, Bussone G (1991) Flunarizine in migraine: a minireview. Headache 31:388-391
17. Le Marec N, Ethier K, Rompre PP, Godbout R (2002) Involvement of the medial prefrontal cortex in two alternation tasks using different environments. Brain Cogn 48:432-436
18. Meltzer HY, Davidson M, Glassman AH, Vieweg WV (2002) Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 63:25-29
19. Ninan I, Kulkarni SK (1999) Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine. Eur J Pharmacol 368:1-7
20. 1 agonist C-APB in mice. Psychopharmacology 145:237-250
21. Pani L, Kuzmin A, Stefanini E, Gessa GL, Rossetti ZL (1990) Flunarizine potentiates cocaine-induced dopamine release and motor stimulation in rats. Eur J Pharmacol 190:223-227
22. + channels involved in neuronal cell death. Protection by flunarizine. Life Sci 48:1881-1893
23. Perkins DO (2002) Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63:1121-1128
24. Phillis JW, Wu PH, Coffin VL (1983) Inhibition of adenosine uptake into rat brain synaptosomes by prostaglandins, benzodiazepines and other centrally active compounds. Gen Pharmacol 14:475-479
25. Popoli P, Pezzola A, Scotti de Carolis A (1990) Possible involvement of the adenosinergic system in flunarizine anti-convulsant activity in rats. Arch Int Pharmacodyn Ther 306:45-56
26. Popoli P, Pezzola A, Benedetti M, Scotti de Carolis A (1992) Verapamil and flunarizine inhibit phencyclidine-induced effects: an EEG and behavioural study in rats. Neuropharmacology 31:1185-1191
27. Rosenzweig-Lipson S, Barrett JE (1995) Modification of the behavioral effects of (±) BAY k 8644, cocaine and d-amphetamine by L-type calcium channel blockers in squirrel monkeys. J Pharmacol Exp Ther 274:842-851
28. Schmidt R, Oestreich W (1991) Flunarizine in the treatment of vestibular vertigo: experimental and clinical data. J Cardiovasc Pharmacol 18:S27-S30
29. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3:123-134
30. 4 receptors. Neuropsychopharmacology 16:93-110
31. Sukhotina IA, Dravolina OA, Medvedev IO, Bespalov AY (1999) Effects of calcium channel blockers on behaviors induced by the N-methyl-D-aspartate receptor antagonist, dizocilpine, in rats. Pharmacol Biochem Behav 63:569-580
32. Todd PA, Benfield P (1989) Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs 38:481-499
33. 3H-tetracaine. Naunyn-Schmiedeberg's Arch Pharmacol 335:176-182
34. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2002) Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159:255-262